<DOC>
	<DOCNO>NCT00144690</DOCNO>
	<brief_summary>The primary objective study determine maximal tolerate dose ( MTD ) E2007 give twice daily ( bid ) day ( qd ) patient refractory partial-onset seizure ( include secondarily generalize seizure ) . The secondary objective evaluate safety , efficacy , concentration-efficacy relationship , pharmacokinetics E2007 effect E2007 Profile Mood States ( POMS ) test .</brief_summary>
	<brief_title>E2007 Given Adjunctive Therapy Patients With Refractory Partial Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Provide write informed consent sign patient legal guardian prior enter study undergo study procedure . Are reliable willing make available study period able record seizures report adverse event caregiver record report event . Male female patient eligible enrollment . Females either nonchildbearing potential result surgery , radiational therapy , menopause ( one year post onset ) , childbearing potential practicing medically acceptable method contraception ( eg , abstinence , barrier method plus spermicide , intrauterine device [ IUD ] ) least three month Visit 1 ( Screening ) two month end study . They must also negative serum betahuman chorionic gonadotropin ( betahCG ) Screening . Pregnant and/or lactate female exclude . Those woman use oral contraceptive must also use additional approve method contraception ( eg , barrier method plus spermicide , IUD ) start Baseline Phase continue throughout entire study period . Are age 18 70 year age , inclusive . Are 40 kg ( 88 lb ) weight . Have diagnosis epilepsy partialonset seizure without secondarily generalize seizures accord International League Against Epilepsy 's Classification Epileptic Seizures ( 1981 ) . Diagnosis establish clinical history , electroencephalogram ( EEG ) compute tomography/magnetic resonance imaging ( CT/MRI ) brain perform within last 10 year consistent localizationrelated epilepsy . Have uncontrolled partial seizure despite treat least three different antiepileptic drug ( AEDs ) ( give concurrently sequentially ) least 2 year . To enrol , patient must average least 4 partial seizure per month , 21day seizurefree period 2 month precede randomization . To randomize , patient must least 3 seizure prospective Baseline Phase ( 28 day ) , 21day seizurefree period . This documented form medical history , medical record , photocopy record patient diary/patient chart . Simple partial seizure without motor sign count towards inclusion criterion . Are currently treat one maximum two license AEDs known take medication ( ) direct . Are stable dose ( ) AED ( ) 2 month prior Visit 1 . If use vagal nerve stimulator , must implant least 5 month prior Visit 1 . Stimulator parameter may change least 1 month prior Visit 1 thereafter study . Magnet use allow document throughout study . Have participate study involve administration investigational compound within one month Visit 1 ( Screening ) , within 5 halflives previous investigational compound , whichever longer . Presence nonmotor simple partial seizure . Presence primary generalize epilepsy seizure , absence , myoclonic epilepsy , LennoxGastaut syndrome . History status epilepticus past year seizure cluster individual seizure count . Show evidence clinically significant disease ( cardiac , respiratory , gastrointestinal , renal disease , etc ) opinion Investigator ( ) could affect patient 's safety trial conduct . Show evidence significant active hepatic disease . Stable elevation liver enzyme , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) due concomitant medication ( ) allow less 2 time upper limit normal ( ULN ) . Show evidence significant active hematological disease . White blood cell ( WBC ) count &lt; = 2500/µL absolute neutrophil count &lt; = 1000/µL . Clinically significant electrocardiogram ( ECG ) abnormality , include prolonged QTc define &gt; = 450 msec male &gt; = 470 msec female . Presence major active psychiatric disease . Patients take stable dose selective serotonin reuptake inhibitor ( SSRI ) antidepressant allow ( except fluvoxamine ) . Presence progressive central nervous system ( CNS ) disease , include degenerative CNS diseases tumor . Have history psychogenic seizure . Have history drug abuse and/or positive finding urinary drug screening , prescribed medication . Have history alcohol abuse past 2 year , and/or positive find urinary drug screen . Have multiple drug allergy ( dermatological , hematological organ toxicity ) one severe drug reaction . Allergy lactose . Concomitant use felbamate use felbamate within 2 month prior Visit 1 . Concomitant use vigabatrin . Patients take vigabatrin past must vigabatrin least 5 month prior Visit 1 must evidence clinically significant abnormality visual perimetry test . Concomitant use use within previous 4 week prior Visit 1 neuroleptic , monoamine oxidase ( MAO ) inhibitor , barbiturate ( except seizure control indication ) , benzodiazepine ( occasional intermittent use ) , narcotic analgesic . Frequent need rescue benzodiazepine ( one time month ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Epilepsy refractory partial seizure</keyword>
</DOC>